Sonali Smith to Thalidomide
This is a "connection" page, showing publications Sonali Smith has written about Thalidomide.
Connection Strength
0.867
-
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Lancet Haematol. 2017 Apr; 4(4):e176-e182.
Score: 0.566
-
Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. Br J Haematol. 2008 Feb; 140(3):313-9.
Score: 0.301